Course Type: On-Demand Webcourse
Number of Credits: 1
Credit Type: CME/MOC/MIPS
Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy will review how to use the risk assessment tool, and the 2018 LDL-C guidelines, including the role of the nonstatin agents ezetimibe and PCSK9 inhibitors. Expert faculty will discuss the role of bempedoic acid, an agent recently approved for LDL-C management, as well as results from trials of inclisiran, an agent in late-stage development.
Ty J. Gluckman, MD, FACC, FAHA
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This activity is supported by educational funding provided by Amgen and Esperion.